Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Generate Sizable License Revenue from IP Growth, Expanding Patent Suite

• Lexaria, a global innovator in drug delivery platforms, has, since 2014, continuously worked on its patented DehydraTECH(TM) drug delivery technology
• The technology has demonstrated overall effectiveness in enhanced delivery of fat-soluble molecules through the human gastrointestinal system, as affirmed by clinical testing
• This overall effectiveness and push for its development has earned Lexaria 37 granted patents globally, with many patents pending
• The company is constantly enhancing its patent portfolio, since granted patents can support an increase in licensing revenue

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is eyeing growth in license revenue from its intellectual property (“IP”). Since 2014, the company has continuously worked on its flagship technology – the patented DehydraTECH(TM) drug delivery technology – which has demonstrated the improvement of speed of onset, brain absorption, and bioavailability (https://ibn.fm/KSkD1). It is being investigated in association with dementia treatment, nicotine replacement, hypertension, and heart disease treatment, among other applications (https://ibn.fm/ItdVS).

So far, Lexaria has received 37 granted patents globally, with many patents pending. The company is aggressively pushing its patent application process as it recognizes the viable commercial application of its flagship technology. In addition, the company understands that successfully granted patents can lead to an increase in shareholder value as a recognized growing market leader.

“Because of the applicability of DehydraTECH to many market sectors across the globe, we have taken the necessary steps to protect that intellectual property internationally,” notes the company’s 2022 Form 10-K annual report (https://ibn.fm/xxsuF).

Lexaria’s patent portfolio currently spreads across the US, Australia, Japan, Mexico, the European Union, Canada and India. Its strategic approach of filing for applications in lucrative markets is a move to maximize potential revenue for years to come, mainly since out-licensing is a significant revenue stream for the company. DehydraTECH applications have shown that it can be applied in the consumer-packaged goods industry and the drug and pharmaceutical sectors. It has demonstrated suitability in various consumer formats such as oral suspensions, capsules, pills and tablets, nutraceuticals, registered drugs, and topical applications (https://ibn.fm/ZP6LI).

This is all made possible by DehydraTECH’s overall effectiveness in delivering most fat-soluble molecules through the human gastrointestinal system, as demonstrated by its overall effectiveness in crossing the blood-brain barrier once within blood plasma. Test data, both in vitro, in vivo, and human clinical testing, has shown that DehydraTECH reduces the time required to enter the bloodstream. It has also shown an increase in absorption rate, as well as the improvement of the taste and smell of edible products.

“Our current patent portfolio includes patent family applications or grants pertaining to our method of improving bioavailability and taste, and the use of DehydraTECH as a delivery platform for a wide variety of APIs including, but not limited to fat-soluble vitamins; anti-viral drugs; phosphodiesterase inhibitors; human hormones; regulated cannabinoids; and nicotine and its analogs,” notes Lexaria’s most recent Form 10-Q quarterly report (https://ibn.fm/A8THJ).

In June 2023, Lexaria received its latest two granted patents in Canada, bringing the total in the country to five. This followed the staggered receipts of three patents in the country in less than a year, a milestone that recognizes and protects the company’s improved compositions and methods for transdermal and dermal delivery of cannabinoids such as tetrahydrocannabinol (“THC”) and CBD. As it continues to push for more approvals, the company is steadily propping itself up for even more success, stamping its position as a leader in its space. More importantly, it is echoing its commitment to creating shareholder value.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, CA
www.TinyGems.com
310.299.1717 Office
Editor@TinyGems.com

TinyGems is powered by IBN